First Biosimilar Trastuzumab approved in the US
Category: Innovation
‘KRABEVA®’s Unique ‘Qual-Check’ Mechanism Ensures Patients Get a Quality-Ascertained Product’: Suresh Subramanian
Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
Antimicrobial Resistance (AMR) – A global threat is here to stay!
Antimicrobial resistance (AMR) represents a global catastrophe that threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
Personalized Medicine – Myth or Reality?
By Sreesha Srinivasa, PhD
Associate Vice President, Research and Development, Biocon Research Limited.
Antibodies as Drugs
By Narendra Chirmule, PhD
Senior VP & Head of Research and Development,
Biocon Research Limited.
Can India Create the Next Apple or Google?
By Kiran Mazumdar Shaw
Chairman & Managing Director,
Biocon Limited.
Anemia – Sickle Cell Disease
By Narendra Chirmule, PhD
Senior Vice President & Head,
Research and Development,
Biocon Research Limited.
